Abstract

Aim: Sarcosine has been identified as a differential metabolite that is greatly increased during progression from normal tissue to prostate cancer and metastatic disease. In this study we assessed the role of serum sarcosine in metastatic castration-resistant prostate cancer (mCRPC) patients. Patients & methods: Data from 52 mCRPC patients treated with docetaxel-based chemotherapy were retrospectively analyzed. Receiver operating characteristic curves, and Kaplan-Meier and Cox multivariate analyses were performed. Results: Median sarcosine values were significantly higher in mCRPC versus non-mCRPC patients (0.81 vs 0.52 nmol/µl; p < 0.0001). A significant correlation resulted between serum sarcosine levels and the duration of hormone sensitivity (Spearman's correlation coefficient: -0.51; p = 0.001). At multivariate analysis sarcosine was an independent prognostic factor of outcome in terms of overall and progression-free survival. Conclusion: Serum sarcosine values were significantly increased in patients with metastatic disease. Moreover, this biomarker is a risk factor for progression and survival in chemotherapy-treated mCRPC patients.

Autore Pugliese

• Bettocchi Carlo , Germinario Cinzia Annatea , Maiorano Eugenio , Fanelli Margherita , Battaglia Michele , Ditonno Pasquale

Tutti gli autori

• BETTOCCHI C.;GERMINARIO C.A.;MAIORANO E.;LUCARELLI G.;FANELLI M.;BATTAGLIA M.;RUTIGLIANO M.;DITONNO P.

Titolo volume/Rivista

Non Disponibile

Anno di pubblicazione

2013

ISSN

1082-331X

ISBN

Non Disponibile

Numero di citazioni Wos

17

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

17

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile